Globus Medical (NYSE:GMED) Raised to “Hold” at UBS Group

Globus Medical (NYSE:GMED) was upgraded by UBS Group to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other analysts have also commented on the stock. Stifel Nicolaus reduced their price objective on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research note on Wednesday, July 8th. BMO Capital Markets started coverage on shares of Globus Medical in a research report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective on the stock. Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Truist Financial reduced their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Finally, Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Globus Medical Stock Performance

NYSE GMED opened at $80.49 on Tuesday. The stock has a market capitalization of $10.93 billion, a P/E ratio of 18.72, a P/E/G ratio of 1.62 and a beta of 0.95. The business’s fifty day moving average is $79.79 and its two-hundred day moving average is $85.85. Globus Medical has a 1 year low of $51.79 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the previous year, the firm posted $0.68 EPS. The company’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts forecast that Globus Medical will post 4.74 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

Institutional investors have recently modified their holdings of the stock. Elevation Wealth Partners LLC grew its holdings in shares of Globus Medical by 2,178.6% during the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 305 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the third quarter worth $26,000. EverSource Wealth Advisors LLC raised its holdings in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.